Basket cover image
4 handpicked stocks

China AI

Once overlooked, Chinese tech giants are now the new darlings of global investors. This collection features companies positioned to become AI champions in the world's second-largest economy, carefully selected by our expert analysts.

stock
stock
stock
stock
Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at mai 5

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

BABA

Alibaba Group

BABA

Current price

$119.99

BIDU

Baidu, Inc.

BIDU

Current price

$89.07

JD

JD.com, Inc.

JD

Current price

$31.24

About This Group of Stocks

1

Our Expert Thinking

DeepSeek's AI breakthrough sparked investor excitement for Chinese tech stocks. Global markets are betting these companies can develop cost-effective AI models while potentially replicating the success of US tech giants like Nvidia, Meta, and Microsoft.

2

What You Need to Know

Chinese tech companies are rapidly increasing AI investments and forming strategic partnerships rather than solely developing in-house solutions. Their nimble approach and access to China's vast market could provide unique advantages in the global AI race.

3

Why These Stocks

These specific companies represent China's technology leaders with significant AI commitments and resources. Each is actively integrating AI into their platforms and services, positioning themselves at the forefront of China's artificial intelligence ambitions.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+32.57%

Group Performance Snapshot

32.57%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 32.57% over the next year.

4 of 4

Stocks Rated Buy by Analysts

4 of 4 assets in this group are rated Buy by professional analysts.

0.6%

Group Growth

This group averaged a 0.6% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚀

The DeepSeek Effect

DeepSeek's breakthrough sparked a frenzy, with Tencent surging 15% after announcing plans to integrate the technology into Weixin. This could be just the beginning of a larger AI revolution in China.

💡

From Overlooked to Opportunity

These once unloved Chinese tech giants are rapidly transforming into AI champions. Could they follow the stellar trajectory of US counterparts like Nvidia and Microsoft?

🔍

Innovation at Lower Costs

China's approach to developing cheaper, nimbler AI models could disrupt the global market. Experts are closely watching these companies for signs of competitive advantages.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Beyond The App Store: Europe's New Rules

Beyond The App Store: Europe's New Rules

Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.

View stocks
The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.